196
Views
15
CrossRef citations to date
0
Altmetric
Original Articles

Co-administration of resveratrol and beta-aminopropionitrile attenuates liver fibrosis development via targeting lysyl oxidase in CCl4-induced liver fibrosis in rats

, , & ORCID Icon
Pages 644-651 | Received 20 Aug 2019, Accepted 27 Oct 2019, Published online: 14 Nov 2019

References

  • Caballería L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol. 2018;16:1138–1145.e5.
  • Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115:209–218.
  • Li S, Tan HY, Wang N, et al. The role of oxidative stress and antioxidants in liver diseases. Int J Mol Sci. 2015;16:26087–26124.
  • Xu F, Liu C, Zhou D, et al. TGF-β/SMAD pathway and its regulation in hepatic fibrosis. J Histochem Cytochem. 2016;64:157–167.
  • Campana L, Iredale JP. Regression of liver fibrosis. Seminars in liver disease. 2017;37:1–10.
  • Liu SB, Ikenaga N, Peng Z-W, et al. Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice. FASEB J. 2016;30:1599–1609.
  • Ikenaga N, Peng Z-W, Vaid KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017;66:1697.
  • Bahabadi M, Mohammadalipour A, Karimi J, et al. Hepatoprotective effect of parthenolide in rat model of nonalcoholic fatty liver disease. Immunopharmacol Immunotoxicol. 2017;39:233–242.
  • Mohseni R, Karimi J, Tavilani H, et al. Carvacrol ameliorates the progression of liver fibrosis through targeting of Hippo and TGF-β signaling pathways in carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Immunopharmacol Immunotoxicol. 2019;41:163–171.
  • Abbasi Oshaghi E, Goodarzi MT, Higgins V, et al. Role of resveratrol in the management of insulin resistance and related conditions: mechanism of action. Crit Rev Clin Lab Sci. 2017;54:267–293.
  • Asadi S, Goodarzi MT, Saidijam M, et al. Resveratrol attenuates visfatin and vaspin genes expression in adipose tissue of rats with type 2 diabetes. Iran J Basic Med Sci. 2015;18:537.
  • Abbasi Oshaghi E, Pourjafar M, Mirzajani SS, et al. Antioxidant properties of resveratrol on acetaminophen induced toxicity in wistar rat liver and HepG2 cells. Avicenna J Med Biochem. 2017;5:81–86.
  • Mohseni R, Abbasi-Oshaghi E, Ghasemi Basir HR, et al. Amelioration of acetaminophen-induced hepatotoxicity in rat by co-administration of quercetin and resveratrol in rats. J Diet Vet Sci. 2019;11: 555817. DOI: 10.19080/JDVS.2019.11.555817.
  • Hong S-W, Jung KH, Zheng H-M, et al. The protective effect of resveratrol on dimethylnitrosamine-induced liver fibrosis in rats. Arch Pharm Res. 2010;33:601–609.
  • Karimi J, Mohammadalipour A, Sheikh N, et al. Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl4)-induced liver fibrosis in rats. Drug Chem Toxicol. 2018:1–11. DOI:10.1080/01480545.2018.1504960.
  • Brasselet C, Durand E, Addad F, et al. Collagen and elastin cross-linking: a mechanism of constrictive remodeling after arterial injury. Am J Physiol Heart Circ Physiol. 2005;289:H2228–H2233.
  • Mohammadalipour A, Karimi J, Khodadadi I, et al. Dasatinib prevent hepatic fibrosis induced by carbon tetrachloride (CCl4) via anti-inflammatory and antioxidant mechanism. Immunopharmacol Immunotoxicol. 2017;39:19–27.
  • Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–254.
  • Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem. 1996;29:225–229.
  • Shirin Sharifi RM, Amiri I, Tavilani H. Sperm matrix metalloproteinase-2 activity increased in the pregnant couples treated with intrauterine insemination: a prospective case control study. J Obstet Gynaecol. 2018;39:675–680.
  • Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38:1103–1111.
  • Yagi K. Assay for blood plasma or serum. Methods Enzymol. 1984;105:328–331.
  • Hu ML. Measurement of protein thiol groups and glutathione in plasma. Methods Enzymol. 1994;233:380–385.
  • Cichoż-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014;20:8082.
  • Arias N, Macarulla MT, Aguirre L, et al. Liver delipidating effect of a combination of resveratrol and quercetin in rats fed an obesogenic diet. J Physiol Biochem. 2015;71:569–576.
  • Miana M, Galán M, Martínez-Martínez E, et al. The lysyl oxidase inhibitor, β-aminopropionitrile, reduces body weight gain and improves the metabolic profile in diet-induced obesity. Dis Model Mech. 2015;8:543–551.
  • Georges PC, Hui J-J, Gombos Z, et al. Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G1147–G1154.
  • Zhang Y-Q, Liu Y-J, Mao Y-F, et al. Resveratrol ameliorates lipopolysaccharide-induced epithelial mesenchymal transition and pulmonary fibrosis through suppression of oxidative stress and transforming growth factor-β1 signaling. Clin Nutr. 2015;34:752–760.
  • Amália PM, Possa MN, Augusto MC, et al. Quercetin prevents oxidative stress in cirrhotic rats. Dig Dis Sci. 2007;52:2616–2621.
  • Martínez-Revelles S, García-Redondo AB, Avendaño MS, et al. Lysyl oxidase induces vascular oxidative stress and contributes to arterial stiffness and abnormal elastin structure in hypertension: role of p38MAPK. Antioxid Redox Signal. 2017;27:379–397.
  • Kessoku T, Imajo K, Honda Y, et al. Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis. Sci Rep. 2016;6:22251.
  • Wang P, Koyama Y, Liu X, et al. Promising therapy candidates for liver fibrosis. Front Physiol. 2016;7:47.
  • Chávez E, Reyes-Gordillo K, Segovia J, et al. Resveratrol prevents fibrosis, NF-κB activation and TGF-β increases induced by chronic CCl4 treatment in rats. J Appl Toxicol. 2008;28:35–43.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.